Kunyuan W. Wang

No. 1838 North Guangzhou Avenue
Guangzhou, 510515, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Corrigendum to "Machine learning algorithms develop a tumor-educated platelets-related gene signature to predict colorectal cancer prognosis and therapy response" [iScience 29 (2026) 116229].

Corrigendum to "Machine learning algorithms develop a tumor-educated platelets-related gene signature to predict colorectal cancer prognosis and therapy response" [iScience 29 (2026) 116229].

Journal: iScience

Published: August 28, 2026

On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial.

On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial.

Journal: The lancet. Gastroenterology & hepatology

Published: May 07, 2026

Immune Checkpoint Inhibitor-Induced Rapid Decline in Hepatitis B Virus Markers Improves the Prognosis of Hepatitis B Virus-Related Hepatocellular Carcinoma Patients.

Immune Checkpoint Inhibitor-Induced Rapid Decline in Hepatitis B Virus Markers Improves the Prognosis of Hepatitis B Virus-Related Hepatocellular Carcinoma Patients.

Journal: The Journal of infectious diseases

Published: October 16, 2025

Clinical efficacy and safety of icaritin in patients with hepatocellular carcinoma: a real-world study.

Clinical efficacy and safety of icaritin in patients with hepatocellular carcinoma: a real-world study.

Journal: Frontiers in pharmacology

Published: August 01, 2025

Machine learning algorithms develop a tumor-educated platelets-related gene signature to predict colorectal cancer prognosis and therapy response.

Machine learning algorithms develop a tumor-educated platelets-related gene signature to predict colorectal cancer prognosis and therapy response.

Journal: iScience

Published: July 24, 2025

Matching-adjusted indirect comparison of tislelizumab plus lenvatinib versus sintilimab plus bevacizumab biosimilar as first-line treatment for unresectable hepatocellular carcinoma.

Matching-adjusted indirect comparison of tislelizumab plus lenvatinib versus sintilimab plus bevacizumab biosimilar as first-line treatment for unresectable hepatocellular carcinoma.

Journal: Frontiers in immunology

Published: March 17, 2025

Radiotherapy enhances the anti-tumor effect of CAR-NK cells for hepatocellular carcinoma.

Radiotherapy enhances the anti-tumor effect of CAR-NK cells for hepatocellular carcinoma.

Journal: Journal of translational medicine

Published: May 17, 2024

Deciphering the influence of AP1M2 in modulating hepatocellular carcinoma growth and Mobility through JNK/ErK signaling pathway control.

Deciphering the influence of AP1M2 in modulating hepatocellular carcinoma growth and Mobility through JNK/ErK signaling pathway control.

Journal: Gene

Published: March 25, 2024

Spleen-dedicated stiffness measurement performed well to rule out high-risk varices in HBV-related hepatocellular carcinoma: Screening for high-risk varices in HCC.

Spleen-dedicated stiffness measurement performed well to rule out high-risk varices in HBV-related hepatocellular carcinoma: Screening for high-risk varices in HCC.

Journal: Alimentary pharmacology & therapeutics

Published: October 23, 2023

Evaluation of an artificial intelligence-based clinical trial matching system in Chinese patients with hepatocellular carcinoma: a retrospective study.

Evaluation of an artificial intelligence-based clinical trial matching system in Chinese patients with hepatocellular carcinoma: a retrospective study.

Journal: BMC cancer

Published: August 31, 2023

Circ_MAPK9 promotes STAT3 and LDHA expression by silencing miR-642b-3p and affects the progression of hepatocellular carcinoma.

Circ_MAPK9 promotes STAT3 and LDHA expression by silencing miR-642b-3p and affects the progression of hepatocellular carcinoma.

Journal: Biology direct

Published: August 27, 2023

Berberine enhances the anti-hepatocellular carcinoma effect of NK92-MI cells through inhibiting IFN-gamma-mediated PD-L1 expression.

Berberine enhances the anti-hepatocellular carcinoma effect of NK92-MI cells through inhibiting IFN-gamma-mediated PD-L1 expression.

Journal: Liver research (Beijing, China)

Published: March 20, 2022

Showing 1-12 of 27

Last Updated: 09/26/2026